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database would not be outdated prior to the end of the study, it 
was necessary to incorporate state-of-the-art MR systems and 
acquisition pulse sequences into the study. Use of 3 Tesla (3T) 
MR systems were selected for the study and several pilot investi- 
gations were undertaken to identify appropriate acquisition proto- 
cols and to cross-validate the quantitative MR measurements to 
those validated irectly. 
The first pilot study, conducted at Ohio State University (OSU), 
had as a goal to help select the optimal acquisition, including 
planes, parameters and pulse sequences for the OAI. MR images 
were obtained in thirteen knees at 3T using sixteen different ac- 
quisitions. These initial MR acquisitions were selected by the OAI 
Imaging Committee after several rounds of protocol optimization 
had been performed. 
Nine 3D series, including two multi-planar eformats (MPRs), 
were evaluated for suitability for cartilage segmentation by five 
persons from cartilage segmentation teams. Nine 2D series, in- 
cluding two multi-slice multi-echo (MSME) T2 map acquisitions, 
were evaluated by six musculoskeletal radiologists for suitabil- 
ity to assess joint structural integrity as well as for discrimi- 
nation of cartilage defects, bone marrow edema-like (BME) le- 
sions and bone cysts. Evaluation criteria included cartilage con- 
trast/structure discrimination relative to surrounding tissues, pres- 
ence/extent of image artifacts, anatomic coverage, fat suppres- 
sion uniformity, and signal uniformity. 
A second pilot study for the OAI, conducted at OSU and Memorial 
Hospital of Rhode Island (MHRI), acquired test-retest MR images 
in the knees of 19 subjects with no to moderate degrees of clin- 
ical OA. Two studies with double oblique coronal 3D FLASH se- 
quences with water excitation (WE) and 1.5mm slice thickness 
were acquired at 3T. In addition, two studies with sagittal 3D 
DESS WE sequences with 0.7mm slice thickness were also ac- 
quired. From the sagittal 3D DESS acquisitions, double oblique 
coronal multi-planar reformats (MPR) were performed at 1.5mm 
slice thickness. 
Knee cartilage volume, surface area, thickness and subcortical 
bone surface area were quantified by four analysis teams in an 
unpaired manner from the 114 image series. Subject identifica- 
tion, image pairs and series were blinded. Regions of interest 
and segmentation rules were determined by concensus of all four 
teams prior to distribution of the blinded images. 
The MR imaging protocol which resulted from the initial pilot study 
will be presented. In addition, a summary of the range of individ- 
ual team results as well as the meta-analysis of the segmentation 
results from the second pilot study will be presented along with a 
description of the subject cohort. A synopsis of the ongoing MR 
pilot studies will also be presented. 
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OA BIOMARKERS: THE CLINICAL TRIAL PERSPECTIVE. 
RADIOGRAPHY 
Marie-Pierre Hellio Le Graverand 
Conventional radiography is the simplest and least expensive 
method for imaging joints in osteoarthritis (OA). Radiographs 
clearly visualize bony features including marginal osteophytes, 
subchondral sclerosis and subchondral cysts that are associated 
with OA but provide only an estimate of cartilage thickness by 
the interbone distance or joint space width (JSW). Radiography 
is used in clinical practice to establish the diagnosis and to moni- 
tor the progression of OA. Various radiographic definitions of OA 
have been proposed. The radiographic definition of OA relies pri- 
marily on the evaluation of both osteophytes and joint space nar- 
rowing (JSN), while the assessment of OA severity relies largely 
on JSN and subchondral bone lesions. Progression of JSN is the 
most commonly used criterion for the assessment of OA progres- 
sion and the complete loss of JSW characterized by bone on 
bone contact is a factor considered in the decision for joint re- 
placement. The growing number of publications on radiographic 
assessment of OA over the recent past years highlights a re- 
newed interest in the assessment of disease progression driven 
in particular by randomized controlled clinical trials (RCTs) for 
Disease Modifying OA Drugs (DMOADs). In the past, studies 
generally used standard plain radiographs (i.e., anteroposterior 
(AP) view of the pelvis for the hip and standing AP view of the 
femorotibial joint for the knee). In recent years, the precision and 
sensitivity of standard plain radiographs for detecting early OA 
and measuring disease progression has been questioned. In ad- 
dition, the demonstration of chondroprotection i DMOAD RCTs 
has demonstrated to be a significant challenge using radiogra- 
phy. This presentation will review the limitations of conventional 
radiography and the progress that has been made in the recent 
years. 
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MAGNETIC RESONANCE IMAGING: DISEASE 
MODIFYING OSTEOARTHRITIS DRUG CLINICAL TRIAL 
PERSPECTIVE 
JL Evelhoch 
More sensitive biomarkers of cartilage degradation are needed to 
facilitate development of disease modifying osteoarthritis drugs 
(DMOAD). Over the past decade, magnetic resonance imaging 
(MRI) techniques, with 3-dimensional imaging capability and high 
soft tissue contrast, have been developed for quantifying cartilage 
morphology throughout the knee. Quantitative cartilage morphol- 
ogy measurements by MRI correlate strongly with independent 
measurements made in specimens from cadavers and/or total 
knee arthroplasty. Longitudinal quantitative MRI studies of OA 
patients indicate that total cartilage volume decreases 4-6% per 
year, with twice that regionally. The variability (test-retest) of total 
cartilage volume in single center studies is 3-4% at 1.5 T(esla) 
and is reduced to 2-3% at 3 T. Thus, multi-center studies should 
be able to detect treatment effects on cartilage degradation in 6- 
12 months with a hundred subjects per arm. Due to the face va- 
lidity of MRI cartilage measurements, there is great interest within 
the drug development industry and regulatory bodies to evaluate 
the potential of quantitative MRI measurements of cartilage mor- 
phology as a surrogate endpoint. 
In addition to these morphometric measurements, several MRI 
methods have been developed to assess cartilage composition, 
including T2, TII~, dGEMRIC and sodium imaging. The T2 and 
T11~ methods rely on changes in these MR properties due to al- 
terations in the biophysical environment of water resulting from 
changes in the cartilage composition. The dGEMRIC (delayed 
Gadolinium Enhanced MRI of Cartilage) and sodium imaging 
methods take advantage of the negative charge of glycosamino- 
glycan (GAG, a principal component of aggrecan), which de- 
creases the amount of Gd(DTPA)2- (i.e., most widely used MRI 
contrast agents) and increases the amount of sodium that pen- 
etrates the cartilage. Since dGEMRIC uses the higher sensitiv- 
ity (and resulting spatial resolution) of proton MRI to image the 
contrast agent distribution, its use to non-invasively assess the 
GAG distribution is of particular interest. Aggrecan is lost in hu- 
man cartilage regions with no detectable collagen loss and de- 
grades before collagen during stimulated cartilage breakdown, 
so it may protect cartilage collagen from degradation. Thus, as 
suggested by the observation that in patients with hip dysplasia, 
the dGEMRIC index, but not JSW, correlates with pain and the 
severity of the dysplasia, dGEMRIC measurement of aggrecan 
depletion could provide an early indicator of OA progression or 
drug effect. Further evaluation of the performance of dGEMRIC 
and the other MR-based methods to assess cartilage composi- 
tion in the context of clinical trials is needed to determine their 
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suitability for use as a biomarker in DMOAD development. If suc- 
cessful, these methods could both accelerate the early evalua- 
tion of new molecules and demonstrate preservation on cartilage 
composition to support regulatory submission for licensure. 
6 
SERUM AND URINE BIOCHEMICAL MARKERS FOR USE 
IN OSTEOARTHRITIS CLINICAL TRIALS 
Joanne M Jordan 
Using radiographic outcomes, clinical trials of potential disease 
modifying interventions for development and progression of os- 
teoarthritis, typically last 2 to 3 years. Such trials are expensive, 
difficult o perform, and subject to biases from attrition and other 
methodologic problems. Inability to accurately identify individu- 
als likely to progress, for selection into a disease-modification 
trial, can limit statistical power if insufficient numbers of individ- 
uals develop the outcome under study. More sensitive imaging 
measures of OA outcome, such as magnetic resonance imaging, 
have been discussed. Biochemical markers, measured in serum 
or urine, are also under investigation to substitute for radiographic 
or other OA outcomes that might require a longer trial duration, 
and to help identify individuals whose OA is likely to develop or 
progress quickly. If a biomarker or panel of biomarkers, in con- 
junction with clinical or other easily obtainable measures, were 
able to identify individuals at high risk of rapid OA progression or 
were to predict response to intervention early, then the duration, 
number of study participants, and expense of clinical trials could 
be decreased and efficiency enhanced. 
In 2003, the NIH/NIAMS established The Osteoarthritis Biomark- 
ers Network as an international consortium of five sites engaged 
in innovative approaches to biomarker development and testing 
in OA. This consortium is working to develop a classification 
scheme for OA biomarkers that could provide a consistent ter- 
minology and framework to facilitate research, development, and 
validation of biomarkers. This classification scheme, still under 
development, proposes five categories of markers: 1)Investiga- 
tive; 2) Diagnostic; 3) Burden of disease, encompassing mea- 
sures of disease activity and damage; 4) Prognostic, and 5) Effi- 
cacy (and toxicity) of intervention. These classification categories 
are not mutually exclusive, nor do they necessarily imply that a 
marker must move serially through each of the categories in its 
development. Markers can fulfill criteria in more than one cate- 
gory. This proposed classification scheme, criteria for the cate- 
gories, and examples of current serum and urine biomarkers in 
each category will be discussed. 
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GRADING SYSTEM FOR MOUSE OSTEOARTHRITIS 
Qian Chen, Sonya S Glasson 
In recent years, knockout and transgenic mouse has become a 
widely used model to determine the contribution of a specific 
gene to the development of a disease in viva. Many genes have 
been implicated in the pathogenesis of osteoarthritis (OA). How- 
ever, unlike the OA occurring in human joint cartilage, there is 
no standardized grading system to evaluate the progress of OA 
in mouse joint cartilage. The lack of a uniform mouse OA grading 
system has made comparison of different mouse OA models diffi- 
cult. The goal of this session is to gather the researchers who are 
working in the mouse OA field, and develop a mouse OA grading 
standard that is accepted by the research community. Such stan- 
dardized mouse OA grading system will become a guideline to 
assess the severity of OA in mouse joint cartilage. This session 
will consist of three parts. 
8 
IDENTIFICATION OF TARGETS THROUGH HISTOLOGIC 
EVALUATION OF OSTEOARTHRITIS IN KNOCK OUT 
MICE 
Sonya Glasson 
Introduction: There are no disease-modifying osteoarthritis 
drugs (DMOADs) currently available for the treatment of OA. In 
order to identify which enzymes or cytokines are important in 
viva, studies were performed in knock out (KO) mice that were 
challenged in a surgical instability model. Those KOs showing a 
decrease in OA severity, following histologic evaluation would be 
targets for the development of selective inhibitors. 
Methods: In an IACUC-approved protocol, 12 different 10- 
week old knock-out (KO) and strain-specific wild-type (WT) mice 
had surgical instability induced in their right knees via desta- 
bilization of the medial meniscus (DMM). IL-11~ (B10.RIII WT), 
MMP-3 (B10.RIII WT), COX-l, COX-2 (B6;129) KOs were from 
Taconic. Jak-3 (C57BL6) and MMP-9 KO (FVB/N WT) mice were 
from Jackson Laboratories (Bar Harbor, ME). MMP-12, cPLA2~ 
(C57BL/6 WT), MK2 (DBA), ADAMTS-4, -5, 4/5 (129SvEv WT) 
KO mice were from Wyeth. Ten males per experimental group 
were sacrificed 8 weeks post-operatively. Knees were fixed in 
4% paraformaldehyde, decalcified, stained with Safranin-O and 
scored by 2 blinded observers using a modified semi-quantitative 
system (Chambers et al. 1997) where a higher score reflects 
greater OA severity. Histologic scores were obtained from all four 
quadrants of the joint (MFC, MTP, LFC, LTP)across 12-16 levels 
spaced at 80 i~m intervals. Results were expressed as a sum of 
all scores and could also be expressed as maximal scores across 
the entire joint or within a specific location (MTP). 
Results: Severity of OA varied greatly depending on the WT 
strain, with the most severe OA in the 129/SvEv strain, fol- 
lowed by C57B10.RIII, C57BL/6, FVB/N and DBA. There were 
no differences between MMP-3, COX-l, COX-2, Jak-3, MMP-12, 
cPLA20~, or ADAMTS-4 KO mice and their respective wild-type 
controls. The MMP-9 and MK2 KO mice had higher scores, re- 
flecting more severe OA, than their WT controls. The scores in 
the IL-11~, ADAMTS-5 and ADAMTS-4/5 KOs were significantly 
decreased compared to controls, using any variation of the scor- 
ing scheme, although greater sensitivity was observed using the 
summed method. 
Discussion: Histologic evaluation of mouse knee joints following 
surgical instability is sensitive to the effects of strain and to dis- 
ease modification from IL-11~ or ADAMTS-5 deletion. More severe 
OA could be observed in MMP-9 or MK2 deficient mice, suggest- 
ing that these enzymes could play a protective role, or that other 
enzymes are up-regulated to compensate. The deletion of the 
majority of genes examined showed no impact on the progres- 
sion of OA, suggesting that these have an insignificant role in OA 
progression. 
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DESIGN AND CONDUCT OF CLINICAL TRIALS IN 
OSTEOARTHRITIS 
Marc C Hochberg 
The Osteoarthritis Research Society International has published 
recommendations for the conduct of clinical trials in patients with 
hip or knee osteoarthritis (1) and is developing similar recommen- 
dations for patients with hand osteoarthritis. This session will re- 
view the design of randomized clinical trials focusing on 1) types 
of trials (superiority, equivalence, non-inferiority), 2) types of con- 
trols (placebo, active treatment), 3) inclusion criteria (including 
use of American College of Rheumatology [ACR] classification 
criteria for case definition), 4) exclusion criteria, 5) types of in- 
